Cue Biopharma, Inc. vs. Johnson & Johnson
Johnson & Johnson (JNJ) comes out ahead, leading on 7 of 8 compared factors.
Size & Scale
| CUE | JNJ | |
|---|---|---|
| Market Cap | $269.15 million | $649.40 billion |
| Revenue (TTM) | $37.65 million | $97.93 billion |
| Net Income (TTM) | $-164,108,000 | $21.04 billion |
JNJ leads on 3 of 3 size & scale factors.
Valuation
| CUE | JNJ | |
|---|---|---|
| P/E Ratio | — | 31.22 |
| Price / Book | 116.51 | 7.64 |
| Price / Sales | 7.15 | 6.63 |
JNJ leads on 2 of 2 valuation factors.
Profitability
| CUE | JNJ | |
|---|---|---|
| Net Margin | -435.83% | 21.48% |
| Return on Equity | -7104.24% | 24.76% |
JNJ leads on 2 of 2 profitability factors.
Dividend
| CUE | JNJ | |
|---|---|---|
| Dividend Yield | — | 1.99% |
| Payout Ratio | — | 62.18 |
CUE and JNJ split the dividend factors evenly.
Risk & Sentiment
| CUE | JNJ | |
|---|---|---|
| Short Interest | 0.48% | 0.67% |
CUE leads on 1 of 1 risk & sentiment factors.
Dig deeper: CUE overview, CUE financials, JNJ overview, JNJ financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.